Real-world evidence (RWE) presented at the 2023 Transplantation and Cellular Therapy Meeting compared and contrasted outcomes for patients receiving inpatient vs. outpatient CAR T-cell therapy for mantle cell lymphoma (MCL) and follicular lymphoma (FL). Patients with FL fared better with outpatient treatment, but those fighting MCL had slightly more adverse events (AEs) with outpatient infusions.
According to Ryan Scott, “As CAR T-cell therapies have garnered approvals in both the relapsed/refractory MCL and FL patient populations, there is a continued interest in optimal administration of this treatment option. CAR T-cell therapy is typically administered in the inpatient setting, but as the treatment continues to become more widely used in clinical practice, there is a renewed interest in utilizing the therapy in the outpatient setting.”
To read more, click here.
(Source: OncLive, March 21st, 2023)